-
1.发明公开公开(公告)号：US20230279124A1
公开(公告)日：2023-09-07
申请号：US18005752
申请日：2021-07-14
申请人： GI INNOVATION, INC.
发明人： Myung Ho JANG , Su Youn NAM , Young-Gyu CHO , Young Min OH , Kyungwha LEE , Nahyun OH
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , C07K2317/622 , C07K2319/30
摘要： The present invention relates to a fusion protein dimer comprising an IgE Fc receptor alpha subunit extracellular domain (FcεRIα-ECD) and a fragment of anti-IL-4R antibody; and a composition for treating allergic diseases, comprising the same. The fusion protein dimer according to the present invention exhibits an excellent IgE-binding ability and an excellent serum IgE level-reducing effect. In addition, the present invention elicits a hyperimmune response of IgE, and thus has an excellent effect of inhibiting the activity of cytokines inducing allergic diseases, such as IL-4 and IL-13, and thus may be applied as a medicine for the use of treating or preventing IgE-mediated allergic diseases.
-
公开(公告)号：US20220257693A1
公开(公告)日：2022-08-18
申请号：US17625668
申请日：2020-07-07
申请人： GI INNOVATION, INC.
发明人： Myoung Ho JANG , Bo-Gie YANG , Kyungwha LEE
摘要： A modified IgE Fc receptor having a high content of sialic acid and a pharmaceutical composition contains the modified IgE Fc receptor are disclosed. The polypeptide dimer having a high content of sialic acid not only has excellent safety and persistence in a body as compared with conventionally used anti-IgE antibodies, but also shows strong binding to IgE. Thus, the polypeptide has the advantage of an extended administration cycle. The polypeptide dimer is also an IgE single target substance, and unlike conventional anti-IgE antibodies to which the Fc of IgG1 is applied, does not bind to an Fc gamma receptor. The polypeptide dimer can be usefully used for the prevention or treatment of allergic diseases.
-
搜索结果
2 条记录 (耗时 0.012 秒)
